DENTSPLY SIRONA (NASDAQ:XRAY) Cut to Strong Sell at Zacks Research

Zacks Research cut shares of DENTSPLY SIRONA (NASDAQ:XRAY) from a hold rating to a strong sell rating in a research note released on Monday,Zacks.com reports.

XRAY has been the subject of a number of other reports. UBS Group lowered their price target on DENTSPLY SIRONA from $24.00 to $23.00 and set a “buy” rating for the company in a report on Tuesday, October 28th. Needham & Company LLC reiterated a “hold” rating on shares of DENTSPLY SIRONA in a research note on Friday, September 26th. Wall Street Zen cut shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research report on Saturday, October 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, October 8th. Finally, Barrington Research reduced their target price on DENTSPLY SIRONA from $18.00 to $14.00 and set an “outperform” rating for the company in a report on Monday. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, DENTSPLY SIRONA currently has a consensus rating of “Hold” and an average target price of $16.08.

DENTSPLY SIRONA Price Performance

Shares of XRAY opened at $10.84 on Monday. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of -2.29, a PEG ratio of 0.81 and a beta of 1.00. The firm’s fifty day simple moving average is $12.79 and its 200-day simple moving average is $14.43. DENTSPLY SIRONA has a twelve month low of $10.69 and a twelve month high of $20.59. The company has a current ratio of 1.69, a quick ratio of 1.11 and a debt-to-equity ratio of 1.13.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.37 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.08). The business had revenue of $904.00 million during the quarter, compared to analysts’ expectations of $900.33 million. DENTSPLY SIRONA had a negative net margin of 25.85% and a positive return on equity of 16.33%. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period last year, the company earned $0.50 EPS. DENTSPLY SIRONA has set its FY 2025 guidance at 1.600-1.600 EPS. Equities analysts forecast that DENTSPLY SIRONA will post 1.84 EPS for the current fiscal year.

Hedge Funds Weigh In On DENTSPLY SIRONA

Large investors have recently bought and sold shares of the company. Gabelli Funds LLC increased its holdings in shares of DENTSPLY SIRONA by 5.9% in the 3rd quarter. Gabelli Funds LLC now owns 48,608 shares of the medical instruments supplier’s stock valued at $617,000 after purchasing an additional 2,700 shares in the last quarter. Gamco Investors INC. ET AL increased its holdings in DENTSPLY SIRONA by 38.5% in the third quarter. Gamco Investors INC. ET AL now owns 158,803 shares of the medical instruments supplier’s stock valued at $2,015,000 after buying an additional 44,110 shares in the last quarter. Truepoint Inc. purchased a new position in DENTSPLY SIRONA in the third quarter valued at about $1,396,000. Barclays PLC lifted its position in shares of DENTSPLY SIRONA by 50.1% during the 3rd quarter. Barclays PLC now owns 248,273 shares of the medical instruments supplier’s stock valued at $3,151,000 after acquiring an additional 82,864 shares during the period. Finally, ARK Investment Management LLC boosted its stake in shares of DENTSPLY SIRONA by 6.4% during the 3rd quarter. ARK Investment Management LLC now owns 226,543 shares of the medical instruments supplier’s stock worth $2,875,000 after acquiring an additional 13,584 shares in the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.